Vaccine maker Moderna jumps on Oppenheimer upgrade, 2025 sales growth goal

Moderna shares surged nearly 14% on Tuesday after brokerage Oppenheimer upgraded the stock to “outperform” and the vaccine maker’s CEO reiterated its goal of achieving sales growth in 2025. The company has been aiming to launch several new vaccine products in the market and is optimistic about their forecast sales growth. Analysts are also predicting a positive future for Moderna, and CEO Stéphane Bancel is confident about breaking even by 2026.

小编点评

Moderna has seen a strong rally in its stock after the upgrade and the announcement of its 2025 sales goal. The company's confidence in its future sales and expansion, along with analysts' positive outlook, suggests that it's well-poised for growth.